NewAmsterdam Pharma N.V. (NAMS)
16.09
0.03 (0.19%)
At close: Apr 16, 2025, 1:22 PM
0.19% (1D)
| Bid | 16 |
| Market Cap | 1.77B |
| Revenue (ttm) | 45.31M |
| Net Income (ttm) | -232.13M |
| EPS (ttm) | -2.56 |
| PE Ratio (ttm) | -6.28 |
| Forward PE | -9.3 |
| Analyst | Buy |
| Ask | 16.26 |
| Volume | 131,154 |
| Avg. Volume (20D) | 1,037,352 |
| Open | 15.88 |
| Previous Close | 16.06 |
| Day's Range | 15.73 - 16.24 |
| 52-Week Range | 14.06 - 27.29 |
| Beta | -0.00 |
About NAMS
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein ...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 9, 2021
Employees 68
Stock Exchange NASDAQ
Ticker Symbol NAMS
Analyst Forecast
According to 7 analyst ratings, the average rating for NAMS stock is "Buy." The 12-month stock price forecast is $42, which is an increase of 161.11% from the latest price.
Stock Forecasts1 month ago
+6.09%
NewAmsterdam Pharma shares are trading higher afte...
Unlock content with
Pro Subscription
1 month ago
+10.23%
NewAmsterdam Pharma shares are trading higher after the company reported better-than-expected FY24 sales results.
